Familial Cancer Centre, Peter MacCallum Cancer Centre, Level 3, 10 St Andrews Place, East Melbourne, VIC, 3002, Australia.
Fam Cancer. 2012 Sep;11(3):403-10. doi: 10.1007/s10689-012-9527-5.
Women with germline mutations in BRCA1 and BRCA2 genes have significantly increased lifetime risks of breast and ovarian cancer. To manage both the ovarian and breast cancer risks the current recommendation is undergo a risk reducing salpingo-oophorectomy (RRSO) prior to natural menopause. To date, studies have focussed on quality of life and sexual dysfunction in women who undergo RRSO, but few have reported on the wider physical consequences. We performed a questionnaire study in women with BRCA 1 or 2 gene mutations known to the Peter MacCallum Familial Cancer Centre. We gathered information about ovarian surgery, ongoing follow-up, management of risk factors including osteoporosis, and current severity of menopausal symptoms. Two hundred and nineteen women were surveyed. One hundred and forty-three of 157 responding participants (91 %) reported having RRSO. Sixty one were pre-menopausal at RRSO. Post surgical follow-up rates were generally low, and a minority of women reported recent bone density imaging or pharmaceutical prevention or treatment of osteoporosis. Menopausal symptoms appeared generally mild. No significant differences in symptom severity were observed in women who underwent a pre-menopausal RRSO compared to RRSO after natural menopause. These data indicate that a formalised follow-up protocol is necessary to optimally manage the consequences of a RRSO.
携带 BRCA1 和 BRCA2 基因突变的女性一生中乳腺癌和卵巢癌的风险显著增加。为了降低卵巢癌和乳腺癌的风险，目前的建议是在自然绝经前进行预防性输卵管卵巢切除术（RRSO）。迄今为止，已有研究集中在 RRSO 后女性的生活质量和性功能障碍方面，但很少有研究报告其更广泛的身体后果。我们对已知的彼得麦卡勒姆家族癌症中心的 BRCA1 或 2 基因突变的女性进行了问卷调查。我们收集了有关卵巢手术、正在进行的随访、包括骨质疏松症在内的危险因素管理以及当前绝经症状严重程度的信息。共有 219 名女性接受了调查。在 157 名回应的参与者中，有 143 名（91%）报告接受了 RRSO。61 名在 RRSO 时处于绝经前。术后随访率普遍较低，少数女性报告最近进行了骨密度成像或使用药物预防或治疗骨质疏松症。绝经症状普遍较轻。与自然绝经后接受 RRSO 的女性相比，在绝经前接受 RRSO 的女性的症状严重程度没有显著差异。这些数据表明，需要制定正式的随访方案来优化 RRSO 的后果管理。
